Skip to main content
. 2020 Apr 23;17:128. doi: 10.1186/s12974-020-01773-w

Table 3.

Comparison of different cohorts of seronegative LETM

Publication Patients number Age at LETM onset (range) years Sex ratio AQP4 Ab MOG Ab Median EDSS at nadir (range) Chronic treatment At least one relapse after Follow-up duration, (range) Median EDSS at follow-up (range)
Sepulveda et al. [13] 23 Median 44.5 (20–77)

16 F

7 M

2 NA 7 (3–9) 12/23, 52% 6/20, 30% Median 32 months (6–54) 2.5 (0–8)
Kitley et al. [15] 32 including MS, ADEM Mean 37.74 (± 16.07)

14 F

18 M

0 6 8 (3–8) NA 31% Median 25 months (1.9–169.4) EDSS at recovery 3 (3–8)
Huyn et al. [12] 42 Mean 43.1 (± 9.8)

9 F

33 M

0 0 3 (3–8.5) NA 30, 71% Mean 5.4 ± 2.6 years 2.5 (1–6)
Cobo-Calvo et al. [14] 56 including MS

Median

39.9 (32.3–58.1)

30 F

16 M

0 13 5.0 (3.5–7.8) 19/56, 33.9% 16, 28.6% Median 42.2 months (25–79.5) 2.5 (1.5–4.8)
This cohort 53 Median 38 (16–80)

28 F

25 M

0 0 6 (1–8.5) 29/53, 55% 12/53, 24.5% Median 3.94 years (1.5–12) mean 4.47 years 4 (0–8)

Ab antibody, EDSS Expanded Disability Status Scale, F female, M male, MS multiple sclerosis, ADEM acute disseminated encephalomyelitis